Emerging Head and Neck Tumor Targeting Contrast Agents for the Purpose of CT, MRI, and Multimodal Diagnostic Imaging: A Molecular Review.
Jonathan M NeilioDaniel Thomas GinatPublished in: Diagnostics (Basel, Switzerland) (2024)
This review aims to explore the efficacy of molecular imaging techniques that employ targeted contrast agents in head and neck cancer imaging. Head and neck cancer imaging benefits significantly from the combined advantages of CT and MRI. CT excels in providing swift, high-contrast images, enabling the accurate localization of tumors, while MRI offers superior soft tissue resolution, contributing to the detailed evaluation of tumor morphology in this region of the body. Many of these novel contrast agents have integration of dual-modal, triple-modal, or even dual-tissue targeting imaging, which have expanded the horizons of molecular imaging. Emerging contrast agents for the purpose of MRI and CT also include the widely used standards in imaging such as gadolinium and iodine-based agents, respectively, but with peptide, polypeptide, or polymeric functionalizations. Relevance for patients. For patients, the development and use of these targeted contrast agents have potentially significant implications. They benefit from the enhanced accuracy of tumor detection and characterization, which are critical for effective treatment planning. Additionally, these agents offer improved imaging contrast with the added benefit of reduced toxicity and bioaccumulation. The summarization of preclinical nanoparticle research in this review serves as a valuable resource for scientists and students working towards advancing tumor diagnosis and treatment with targeted contrast agents.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- magnetic resonance
- high resolution
- computed tomography
- cancer therapy
- diffusion weighted imaging
- end stage renal disease
- dual energy
- chronic kidney disease
- image quality
- newly diagnosed
- photodynamic therapy
- drug delivery
- positron emission tomography
- prognostic factors
- stem cells
- peritoneal dialysis
- climate change
- chronic pain
- mass spectrometry
- heavy metals
- pain management
- bone marrow
- patient reported outcomes
- deep learning